Dr. Reddy's Laboratories

RDY

Market cap $11.3B

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 29, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.

HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $RDY #DrReddy--Dr. Reddy's Laboratories Ltd. a global pharmaceutical company, today announced the launch of its generic Semaglutide Injection in Canada.

Dr. Reddy's Laboratories NYSE: RDY reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide sales and several one-time charges during the fourth quarter.

RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.

Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript

Indian drugmaker Dr Reddy's ​reported an 86% ‌slump in quarterly profit on Tuesday, ​hurt by pricing ​pressure and increasing competition ⁠in its ​key U.S. market.

Investors interested in stocks from the Medical - Generic Drugs sector have probably already heard of Amphastar Pharmaceuticals (AMPH) and Doctor Reddy's (RDY). But which of these two companies is the best option for those looking for undervalued stocks?

The country is the first in the G7 forum to approve a generic version of the massively popular GLP-1 diabetes treatment.

HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $RDY #DrReddy--Dr. Reddy's Laboratories Ltd. announced that it has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection.

Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.